Yange P. Tian

Zhengzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 74 publications

Nuclear factor erythroid 2-related factor 2 as targets to treat chronic obstructive pulmonary disease: toward new perspectives.

Nuclear factor erythroid 2-related factor 2 as targets to treat chronic obstructive pulmonary disease: toward new perspectives.

Journal: Therapeutic advances in respiratory disease

Published: August 17, 2026

Effective-Component Compatibility of Bufei Yishen Formula III Improves Chronic Obstructive Pulmonary Disease by Inhibiting Inflammatory Responses Through Blocking PTX3 Activation.

Effective-Component Compatibility of Bufei Yishen Formula III Improves Chronic Obstructive Pulmonary Disease by Inhibiting Inflammatory Responses Through Blocking PTX3 Activation.

Journal: Journal of inflammation research

Published: April 01, 2026

Electroacupuncture mitigates lung injury, increases endogenous antioxidant levels and modulates Nrf2 signaling in a rat model of chronic obstructive pulmonary disease.

Electroacupuncture mitigates lung injury, increases endogenous antioxidant levels and modulates Nrf2 signaling in a rat model of chronic obstructive pulmonary disease.

Journal: Acupuncture in medicine : journal of the British Medical Acupuncture Society

Published: March 17, 2026

Spatial omics in pulmonary fibrosis: advancing mechanistic insights and therapeutic strategies

Spatial omics in pulmonary fibrosis: advancing mechanistic insights and therapeutic strategies

Journal: Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences

Published: February 03, 2026

Micro-CT dynamic changes and molecular mechanisms in a pulmonary nodule mouse model induced by Benzo[a]pyrene and lipopolysaccharide.

Micro-CT dynamic changes and molecular mechanisms in a pulmonary nodule mouse model induced by Benzo[a]pyrene and lipopolysaccharide.

Journal: Journal of thoracic disease

Published: January 30, 2026

Effective-Component Compatibility of Bufei Yishen Formula Alleviates Alveolar Epithelial Barrier Damage in COPD Through Inhibition of p38 MAPK Phosphorylation.

Effective-Component Compatibility of Bufei Yishen Formula Alleviates Alveolar Epithelial Barrier Damage in COPD Through Inhibition of p38 MAPK Phosphorylation.

Journal: International journal of chronic obstructive pulmonary disease

Published: January 12, 2026

Jinshui Chenfei formula alleviates SiO2-induced pulmonary fibrosis by inhibiting macrophage M2 polarization via Grb2/STAT6 in rats.

Jinshui Chenfei formula alleviates SiO2-induced pulmonary fibrosis by inhibiting macrophage M2 polarization via Grb2/STAT6 in rats.

Journal: Chinese medicine

Published: November 03, 2025

Cigarette smoke combined with Klebsiella pneumoniae induce damage to the air‑blood barrier in chronic obstructive pulmonary disease rats via the MAPK/NF‑κB/IκBα pathway.

Cigarette smoke combined with Klebsiella pneumoniae induce damage to the air‑blood barrier in chronic obstructive pulmonary disease rats via the MAPK/NF‑κB/IκBα pathway.

Journal: Molecular medicine reports

Published: July 24, 2025

Yiqi Zishen Formula ameliorates inflammation in mice with chronic obstructive pulmonary disease by inhibiting the PI3K/Akt/NF-κB signaling pathway

Yiqi Zishen Formula ameliorates inflammation in mice with chronic obstructive pulmonary disease by inhibiting the PI3K/Akt/NF-κB signaling pathway

Journal: Nan fang yi ke da xue xue bao = Journal of Southern Medical University

Published: July 17, 2025

Electroacupuncture stimulation improves pulmonary fibrosis by modulating ferroptosis in rats: multiscale analysis of transcriptome and proteome.

Electroacupuncture stimulation improves pulmonary fibrosis by modulating ferroptosis in rats: multiscale analysis of transcriptome and proteome.

Journal: Chinese medicine

Published: March 17, 2025

Effective Component Compatibility of Bufei Yishen Formula III Alleviates Pulmonary Vascular Inflammation in COPD: Via VEGF165/P38 MAPK Pathway.

Effective Component Compatibility of Bufei Yishen Formula III Alleviates Pulmonary Vascular Inflammation in COPD: Via VEGF165/P38 MAPK Pathway.

Journal: Journal of inflammation research

Published: February 17, 2025

Integrating single-cell analysis and machine learning to identify COPD hub genes and explore the intervention mechanism of effective component compatibility of Bufei Yishen formula III.

Integrating single-cell analysis and machine learning to identify COPD hub genes and explore the intervention mechanism of effective component compatibility of Bufei Yishen formula III.

Journal: Journal of ethnopharmacology

Published: February 14, 2025

Showing 1-12 of 74

Last Updated: 09/26/2026